Bausch + Lomb (NYSE:BLCO) EVP Purchases $250,390.00 in Stock

Bausch + Lomb Corporation (NYSE:BLCO) EVP A Robert Bailey bought 14,600 shares of the stock in a transaction dated Friday, March 6th. The stock was acquired at an average price of $17.15 per share, with a total value of $250,390.00. Following the completion of the purchase, the executive vice president owned 231,890 shares of the company’s stock, valued at $3,976,913.50. This represents a 6.72% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Bausch + Lomb Stock Performance

Bausch + Lomb stock opened at $16.59 on Friday. The stock has a 50-day simple moving average of $17.28 and a 200 day simple moving average of $16.20. The stock has a market capitalization of $5.89 billion, a price-to-earnings ratio of -16.26, a P/E/G ratio of 0.74 and a beta of 0.58. The company has a quick ratio of 1.04, a current ratio of 1.55 and a debt-to-equity ratio of 0.77. Bausch + Lomb Corporation has a 12-month low of $10.45 and a 12-month high of $18.92.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings data on Wednesday, February 18th. The company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.03). The company had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.38 billion. Bausch + Lomb had a positive return on equity of 2.77% and a negative net margin of 7.06%.The firm’s revenue was up 9.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.25 EPS. On average, research analysts anticipate that Bausch + Lomb Corporation will post 0.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bausch + Lomb

Several institutional investors have recently modified their holdings of BLCO. Northwestern Mutual Wealth Management Co. grew its position in shares of Bausch + Lomb by 729.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock worth $30,000 after buying an additional 2,042 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in Bausch + Lomb by 104.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock valued at $38,000 after buying an additional 1,136 shares during the period. Wells Fargo & Company MN lifted its holdings in Bausch + Lomb by 31.2% in the fourth quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock valued at $101,000 after buying an additional 1,403 shares during the period. Jones Financial Companies Lllp boosted its stake in Bausch + Lomb by 55.3% in the third quarter. Jones Financial Companies Lllp now owns 9,112 shares of the company’s stock valued at $132,000 after acquiring an additional 3,246 shares during the last quarter. Finally, Focus Partners Wealth bought a new position in Bausch + Lomb in the third quarter valued at approximately $170,000. Institutional investors and hedge funds own 11.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on BLCO. Royal Bank Of Canada increased their price target on shares of Bausch + Lomb from $19.00 to $21.00 and gave the company an “outperform” rating in a research note on Tuesday, January 27th. The Goldman Sachs Group restated a “neutral” rating and issued a $19.00 price objective on shares of Bausch + Lomb in a research report on Friday, January 9th. Evercore set a $18.00 price objective on Bausch + Lomb and gave the stock an “in-line” rating in a report on Monday, January 5th. Barclays increased their price objective on Bausch + Lomb from $17.00 to $20.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Finally, Wells Fargo & Company lifted their target price on Bausch + Lomb from $17.00 to $18.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $18.25.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.